Hikma at a glance
Discover what drives us
Latest news
Featured
Hikma delivers strong 2023 performance and a positive outlook for 2024
Press Release, Financial Results
22 February 2024
- Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA Press Release, Business Development 06 October 2025 Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA
- Inspiring women of Hikma - Meet Christine Schneider, General Manager, Hikma Germany Story, Life at Hikma 06 October 2025 Inspiring women of Hikma - Meet Christine Schneider, General Manager, Hikma Germany
- Driving pharmaceutical excellence and growth in Pavia: A Q&A with Roberto Gagliano, General Manager, Hikma Italia Insight, Life at Hikma 03 October 2025 Driving pharmaceutical excellence and growth in Pavia: A Q&A with Roberto Gagliano, General Manager, Hikma Italia
- Hikma and Richter receive FDA approval for denosumab biosimilars EnobyTM (denosumab- qbde) and XtrenboTM (denosumab- qbde) referencing Prolia® and Xgeva® respectively Press Release, Product 29 September 2025 Hikma and Richter receive FDA approval for denosumab biosimilars EnobyTM (denosumab- qbde) and XtrenboTM (denosumab- qbde) referencing Prolia® and Xgeva® respectively